Sugi Predict

Sugi Predict / Compounds / SCHEMBL1280673

SCHEMBL1280673

SCHEMBL1280673

O=C(O)COc1ncccn1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALOX15 P16050 1/20 0.52
▸ LMNA P02545 1/20 0.46
▸ KMT2A Q03164 4/20 0.45
▸ CD69 Q07108 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ GLA P06280 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ MEN1 O00255 3/20 0.43
▸ PTPN7 P35236 2/20 0.42
▸ FFAR1 O14842 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PTPN12 Q05209 1/20 0.41
▸ PTGDR2 Q9Y5Y4 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6993373 0.88 ALOX15 (0.42) ALOX15LMNAKMT2ACD69POLB
SCHEMBL5859013 0.79 MAPT (0.49) KMT2APOLBGLAL3MBTL1MEN1
SCHEMBL3260741 0.77 LMNA (0.47) LMNAL3MBTL1ALDH1A1
SCHEMBL5360711 0.76 MEN1 (0.65) ALOX15LMNAKMT2APOLBSMN1; SMN2
SCHEMBL6029086 0.76 PTGDR2 (0.44) ALOX15KMT2APOLBL3MBTL1MEN1
SCHEMBL26983245 0.76 TBXA2R (0.46) LMNASMN1; SMN2ALDH1A1
SCHEMBL5207754 0.76 ALOX15 (0.52) ALOX15KMT2APOLBSMN1; SMN2GLA
SCHEMBL30746861 0.74 ALOX15 (0.55) ALOX15LMNAKMT2APOLBSMN1; SMN2
SCHEMBL176214 0.74 ALOX15 (0.55) ALOX15LMNAKMT2APOLBSMN1; SMN2
SCHEMBL315250 0.74 MAPT (0.55) LMNAKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090564-A2 THIOPHENE BASED APYRASE INHIBITORS TEXAS CROP SCIENCE, INC. (US) 2026-04-30 — — WO disclosed
US-20260116872-A1 THIOPHENE BASED APYRASE INHIBITORS TEXAS CROP SCIENCE INC (US) 2026-04-30 — — US disclosed
CN-103261176-B 1, 4-oxazepane derivatives TAKEDA PHARMACEUTICAL 2015-06-03 — — CN disclosed
US-8722662-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-05-13 — — US disclosed
US-20130267494-A1 1,4-OXAZEPANE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-10-10 — — US disclosed
CN-103261176-A 1, 4-oxazepane derivatives TAKAEDA CHEMICAL IND LTD 2013-08-21 — — CN disclosed
EP-2625170-A1 1,4-OXAZEPANE DERIVATIVES Takeda Pharmaceutical Company Limited (JP) 2013-08-14 — — EP disclosed
US-20120088748-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-12 — — US disclosed
WO-2012046882-A1 1,4-OXAZEPANE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-12 — — WO disclosed
EP-1212299-B1 SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA UK LTD (GB) 2009-04-08 — — EP disclosed
US-20050250792-A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT 2005-11-10 — — US disclosed
US-6903085-B1 Substituted piperidine compounds useful as modulators of chemokine receptor activity ASTRAZENECA, AB (CH) 2005-06-07 — — US disclosed
EP-1250340-B1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 LILLY CO ELI (US) 2004-11-17 — — EP disclosed
US-20040176405-A1 Methods and compounds for inhibitting MRP1 KROIN JULIAN (US) 2004-09-09 — — US disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 — — US disclosed
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ELI LILLY AND COMPANY 2003-05-29 — — US disclosed
EP-1250340-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-10-23 — — EP disclosed
EP-1212299-A1 SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca UK Limited (GB) 2002-06-12 — — EP disclosed
WO-2001046199-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-06-28 — — WO disclosed
WO-2001014333-A1 SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA UK LIMITED (GB) 2001-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267494-A1 1,4-OXAZEPANE DERIVATIVES MAOB, SLC6A4, SLC6A2 ALOX15 1305/4885LMNA 4129/4885KMT2A 715/4885
US-20040176405-A1 Methods and compounds for inhibitting MRP1 ABCC1, ABCB11, ABCB1 ALOX15 2848/4885LMNA 2547/4885KMT2A 4688/4885
US-20260116872-A1 THIOPHENE BASED APYRASE INHIBITORS SRR, APEH, OSR1 ALOX15 1832/4885LMNA 4794/4885KMT2A 3764/4885
US-20050250792-A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity CXCR4, CXCR1, CXCR3 ALOX15 3837/4885LMNA 3126/4885KMT2A 2580/4885
US-20120088748-A1 HETEROCYCLIC COMPOUNDS SLC6A2, MAOB, MAOA ALOX15 3188/4885LMNA 3367/4885KMT2A 364/4885
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ABCC1, ABCB11, ABCB1 ALOX15 2922/4885LMNA 2226/4885KMT2A 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.